Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Disc Medicine Shares Skyrocket 45% in 7 Days Since Other

Disc Medicine Reports Success in Phase 3 APOLLO Trial with 41.4% Reduction in PPIX

+45.34% in 7 days $56.84 when we broke this story → $82.61 at 2:35 PM ET, 28 Oct 2026

Disc Medicine has successfully met all primary and secondary endpoints in its pivotal Phase 3 APOLLO trial evaluating bitopertin for patients with erythropoietic protoporphyria. The trial demonstrated a significant 41.4% reduction in toxic PPIX levels and a marked increase in pain-free light tolerance, supporting a planned NDA resubmission by the end of 2026.

Thermometer, temperature, fever, flu. Stock photo illustrating Disc Medicine's other story.
Disc Medicine, Inc. · Healthcare · Photo: stevepb / Pixabay

Key highlights

  • Achieved 41.4% reduction in whole-blood metal-free PPIX compared to placebo with high statistical significance
  • Increased average monthly total time in light without pain by 12.2 hours during the six-month study period
  • Successfully met all secondary endpoints, including significant reductions in phototoxic reaction incidence rates
  • Maintained a favorable safety profile with dizziness being the most commonly reported transient adverse event
  • NDA resubmission for bitopertin targeted for year-end 2026 with an anticipated FDA decision by mid-2027

Phase 3 APOLLO Trial Outcomes

Disc Medicine announced that its pivotal Phase 3 APOLLO trial of bitopertin met its co-primary and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The study randomized 183 participants to receive either 60 mg of oral bitopertin or a placebo daily for six months. Results showed a 41.4% reduction in metal-free protoporphyrin IX (PPIX) levels relative to the placebo group. Additionally, patients treated with bitopertin experienced a statistically significant increase of 12.2 hours in average monthly pain-free light exposure. These findings validate the mechanism of targeting heme synthesis to address the fundamental cause of EPP-related phototoxicity.

Safety and Regulatory Timeline

The safety profile observed in the APOLLO trial was consistent with previous clinical data, showing no new safety signals or adverse events above Grade 3. Dizziness was the most frequent treatment-emergent adverse event, reported by 50% of the bitopertin group, though it was characterized as mild or moderate and generally transient. Following these positive results, Disc Medicine intends to resubmit its New Drug Application (NDA) to the FDA by the conclusion of 2026. This resubmission is expected to trigger a regulatory decision by mid-2027, potentially addressing the requirements established in the previous Complete Response Letter.

Company Operations and Portfolio

  • Disc Medicine specializes in developing therapies for serious hematologic diseases by targeting iron metabolism and heme biosynthesis.
  • Bitopertin is a first-in-class, oral GlyT1 inhibitor designed to modulate the production of toxic protoporphyrin IX.
  • The company is also advancing DISC-3405 for polycythemia vera and DISC-0974 for anemia associated with chronic inflammatory diseases.
  • Research efforts are supported by a global clinical footprint including sites in the United States, Canada, Europe, and Australia.

Financial and Strategic Context

As a clinical-stage biotechnology firm, Disc Medicine does not currently record revenue from commercial product sales. However, the company maintains a strong balance sheet with approximately $718 million in cash, cash equivalents, and marketable securities as of June 30, 2026. Management has indicated that this capital position provides a liquidity runway into 2029, covering the anticipated commercial launch of bitopertin. The firm has also secured non-dilutive financing, including a $200 million term loan facility from Hercules Capital, to ensure flexibility as it transitions toward potential commercialization in the rare disease market.

Disc Medicine, Inc. share price · last month
Line chart of Disc Medicine, Inc.'s share price over the last month, from $78.93 on 19 Oct → $76.59 on 16 Nov; our story on 19 Oct at $56.84.

Up 34.7% since our story on 19 Oct: $56.84 when we broke it → $76.59 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$78.93
20 Oct$79.48
21 Oct$76.00
22 Oct$75.03
23 Oct$74.51
26 Oct$77.66
27 Oct$79.90
28 Oct$83.20
29 Oct$82.84
30 Oct$80.84
2 Nov$78.62
3 Nov$81.16
4 Nov$83.28
5 Nov$78.47
6 Nov$78.91
9 Nov$81.26
10 Nov$84.64
11 Nov$87.08
12 Nov$83.23
13 Nov$80.00
16 Nov$76.59

Executive Perspective

“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”

John Quisel, J.D., Ph.D., President and Chief Executive Officer, Disc Medicine
Earlier announcements by Disc Medicine, Inc.
DateAnnouncementAmount
09 Sep 2026Initial results from the Phase 2 RESTORE-PV trial of DISC-3405 in polycythemia vera presented at SOHO 2026Source: ir.discmedicine.com–
09 Jun 2026Regulatory update on FDA Type A meeting aligning Phase 3 APOLLO trial to support bitopertin CRL responseSource: ir.discmedicine.com–
13 Feb 2026Receipt of FDA Complete Response Letter for bitopertin NDA in erythropoietic protoporphyriaSource: ir.discmedicine.com–
21 Oct 2025Pricing of upsized public offering of common stock and pre-funded warrantsSource: ir.discmedicine.com$250.0 Million
22 Jan 2025Pricing of upsized public offering of common stock and pre-funded warrantsSource: ir.discmedicine.com$225.5 Million
08 Nov 2024Agreement for non-dilutive term loan facility from Hercules CapitalSource: ir.discmedicine.com$200.0 Million

Management commentary

“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”

John Quisel, J.D., Ph.D., President and Chief Executive Officer

“These results are compelling evidence of the clinical benefit of a mechanism aimed at reducing the production of PPIX, the fundamental cause of disease. It has been an incredible journey from establishing the original hypothesis of targeting heme synthesis in cellular models to seeing that biology translate into the clear and meaningful clinical effects from APOLLO.”

Will Savage, M.D., Ph.D., Chief Medical Officer
Disc Medicine, Inc. · financial snapshot
Share price$56.84
Market cap$2.2B
1-month price change-17.11%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Disc Medicine, Inc. announcing topline results from the Phase 3 APOLLO trial of bitopertin.

Read the filing ↗
All Disc Medicine, Inc. filings and newsView all →

Track Disc Medicine, Inc. live

Get the next Disc Medicine, Inc. SEC filing seconds after it lands.

More from Disc Medicine, Inc.

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.